Dabrafenib Mesylate

Phase 3

NNational Cancer Institute (NCI)

Dabrafenib Mesylate is one of 57 therapeutic programs targeting Advanced Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced LymphomaActive, not recruiting

Clinical Stage III Cutaneous Melanoma AJCC V8Active, not recruiting

Clinical Stage IV Cutaneous Melanoma AJCC V8Terminated

Anaplastic AstrocytomaActive, not recruiting

Advanced LymphomaPhase 2

Active, not recruiting

Clinical Stage III Cutaneous Melanoma AJCC V8Phase 3

Active, not recruiting

Clinical Stage IV Cutaneous Melanoma AJCC V8Phase 2

Terminated

Anaplastic AstrocytomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Advanced Lymphoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Phase 2

3 2

Mekinist

Novartis

Phase 2

3 3

Balversa

Johnson & Johnson

Phase 2

2 4

Vitrakvi

Bayer

Phase 2

2 5

Tagrisso

AstraZeneca

Phase 2

2 6

Sutent

Pfizer

Phase 2

2 7

Adavosertib

AstraZeneca

Phase 2

2 8

M6620

AstraZeneca

Phase 2

2 9

Alinamin

Roche

Phase 2

1 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Clinical Stage III Cutaneous Melanoma AJCC V8

NCT02224781

Phase 2Active, not recruiting

Advanced Lymphoma

NCT02465060

Q1 2027

PreclinicalActive, not recruiting

Clinical Stage IV Cutaneous Melanoma AJCC V8

NCT04557956

Phase 2Active, not recruiting

Stage III Cutaneous Melanoma AJCC V7

NCT02196181

Q3 2027

Phase 2Active, not recruiting

Anaplastic Astrocytoma

NCT03919071

Clinical

Trials by Indication[1]

Clinical Stage IV Cutaneous Melanoma AJCC v82 trials

Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT04557956·16 enrolled

The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma With Elevated LDH

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04527549·5 enrolled

Stage III Cutaneous Melanoma AJCC v71 trial

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02196181·280 enrolled

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02224781·267 enrolled

Advanced Lymphoma1 trial

Molecular Analysis for Therapy Choice (MATCH)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02465060·6,452 enrolled

Anaplastic Astrocytoma1 trial

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03919071·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Dabrafenib Mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dabrafenib Mesylate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

Dabrafenib Mesylate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Trials by Indication[1]

Clinical Stage IV Cutaneous Melanoma AJCC v82 trials

Stage III Cutaneous Melanoma AJCC v71 trial

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

Advanced Lymphoma1 trial

Anaplastic Astrocytoma1 trial

References

Drug Info

Quick Facts

Related News